Kodiak Sciences is scheduled to present clinical data for all three of its late-stage assets at the American Academy of Ophthalmology (AAO) Annual Meeting on October 9, 2026.
The presentations will include the first scientific disclosure of the complete one-year primary efficacy and safety outcomes from the pivotal Phase 3 DAYBREAK study. The study evaluates Zenkuda and tabirafusp-ted in patients with wet age-related macular degeneration.
Kodiak announced on September 28, 2026, that DAYBREAK met its primary endpoints. The AAO presentation will provide the full data set to the scientific community for the first time.
Other conference presentations will include data from the Phase 1b APEX study of KSI-101 in macular edema.